

PRODUCT INFORMATION



GSK8612

Item No. 28813

CAS Registry No.: 2361659-62-1

Formal Name: 4-[[[5-bromo-2-[[3-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]amino]-4-pyrimidinyl]amino]methyl]-benzenesulfonamide

MF: $C_{17}H_{17}BrF_3N_7O_2S$

FW: 520.3


Purity: $\geq 95\%$

UV/Vis.: λ_{max} : 228 nm

Supplied as: A solid

Storage: $-20^{\circ}C$

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GSK8612 is supplied as a solid. A stock solution may be made by dissolving the GSK8612 in the solvent of choice, which should be purged with an inert gas. GSK8612 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of GSK8612 in these solvents is approximately 5 and 10 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of GSK8612 can be prepared by directly dissolving the solid in aqueous buffers. The solubility of GSK8612 in PBS (pH 7.2) is approximately 0.3 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

GSK8612 is an inhibitor of TANK-binding kinase 1 (TBK1; $IC_{50} = 158$ nM).¹ It is selective for TBK1 over a panel of 285 kinases. GSK8612 inhibits IFN- α release in isolated human peripheral blood mononuclear cells (PBMCs) stimulated with polyinosinic-polycytidylic acid (poly(I:C); $IC_{50} = 794$ nM). It also inhibits IFN- β secretion in THP-1 cells stimulated with dsDNA-containing baculovirus or cGAMP (IC_{50} s = 1,258 and 501 nM, respectively). GSK8612 (5 mg/kg) reduces tumor volume and increases the number of tumor-infiltrating CD8⁺ T cells in immunocompetent, but not immunodeficient, mice in a model of carbon tetrachloride-induced hepatocellular carcinoma (HCC).²

References

1. Thomson, D.W., Poeckel, D., Zinn, N., *et al.* Discovery of GSK8612, a highly selective and potent TBK1 inhibitor. *Med. Chem. Lett.* **10**(5), 780-785 (2019).
2. Jiang, Y., Chen, S., Li, Q., *et al.* TANK-binding kinase 1 (TBK1) serves as a potential target for hepatocellular carcinoma by enhancing tumor immune infiltration. *Front. Immunol.* **12**, 612139 (2021).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/19/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM